What's new - What's hot in basic science: American Transplant Congress 2004

American Journal of Transplantation

Volumn 4, Issue 11, 2004, Pages 1741-1746

  Kirk, Allan D ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Rejection; Transplantation immunology

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; JANUS KINASE; VASCULOTROPIN;

ALLOIMMUNITY; CONFERENCE PAPER; GRAFT REJECTION; HISTOCOMPATIBILITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; ORGAN TRANSPLANTATION; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; XENOTRANSPLANTATION;

ANIMALS; CONGRESSES; HUMANS; IMMUNOSUPPRESSION; ISLETS OF LANGERHANS TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTATION, HOMOLOGOUS; UNITED STATES;

EID: 7244254576     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00632.x     Document Type: Conference Paper

References (58)

1. Zerhouni E. Medicine: The NIH roadmap. Science 2003; 302: 63-72.
2. Welsh RM, Selin LK. No one is naive: The significance of heterologous T-cell immunity. Nat Rev Immunol 2002; 2: 417-426.
3. Adams AB, Williams MA, Jones TR et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111: 1887-1895.
4. Abstract 524.
5. Valujskikh A, Lakkis FG. In remembrance of things past: Memory T cells and transplant rejection. Immunol Rev 2003; 196: 65-74.
6. Abstract 525.
7. Abstract 527.
8. Abstract 1406.
9. Chalasani G, Li Q, Konieczny BT et al. The allograft defines the type of rejection (acute versus chronic) in the face of an established effector immune response. J Immunol 2004; 172: 7813-7820.
10. Zinkernagel RM. Uncertainties - Discrepancies in immunology. Immunol Rev 2002; 185: 103-125.
11. Zinkernagel RM. On differences between immunity and immunological memory. Curr Opin Immunol 2002; 14: 523-536.
12. Wu Z, Bensinger SJ, Zhang J. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004; 10: 87-92.
13. Sarwal M, Chua MS, Kambham N et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med. 2003; 349: 125-138.
14. Schaub S, Rush D, Wilkins J et al. Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol 2004; 15: 219-227.
15. Abstract 520.
16. Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science 2002; 296: 1653-1655.
17. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol. 2003; 3: 900-911.
18. Changelian PS, Flanagan ME, Ball DJ et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003; 302: 875-878.
19. Abstract 139.
20. Abstract 466.
21. Abstract 97.
22. Abstract 465.
23. Abstract 859.
24. Abstract 1384.
25. Egwuagu CE, Yu CR, Zhang M, Mahdi RM, Kim SJ, Gery I. Suppressors of cytokine signaling proteins are differentially expressed in Th1 and Th2 cells: Implications for Th cell lineage commitment and maintenance. J Immunol 2002; 168: 3181-3187.
26. Jackson SH, Yu CR, Mahdi RM, Ebong S, Egwuagu CE. Dendritic cell maturation requires STAT1 and is under feedback regulation by suppressors of cytokine signaling. J Immunol 2004; 172: 2307-2315.
27. ATC 2004; Abstract 540.
28. Reinders ME, Sho M, Izawa A et al. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest 2003; 112: 1655-65.
29. Reinders M E, Fang JC, Wong W, Ganz P, Briscoe DM. Expression patterns of vascular endothelial growth factor in human cardiac allografts: Association with rejection. Transplantation 2003; 76: 224-230.
30. Abramson LP, Pahl E, Huang L et al. Serum vascular endothelial growth factor as a surveillance marker for cellular rejection in pediatric cardiac transplantation. Transplantation 2002; 73: 153-156.
31. Abstract 1466.
32. Abstract 1.
33. Abstract 912.
34. Akira S, Takeda K. Toll-like receptor signaling. Nat Rev Immunol 2004; 4: 499-511.
35. + T-cell survival. J Immunol 2004; 172: 6065-6073.
36. Goldstein DR, Tesar BM, Akira S, Lakkis FG. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest 2003; 111: 1571-1578.
37. Abstract 548.
38. Abstract 539.
39. Elzey BD, Tian J, Jensen RJ et al. Platelet-mediated modulation of adaptive immunity: A communication link between innate and adaptive immune compartments. Immunity 2003; 19: 9-19.
40. Czapiga M, Kirk AD, Lekstrom-Himes J. Platelets deliver costimulatory signals to antigen-presenting cells: A potential bridge between injury and immune activation. Exp Hematol 2004; 32: 135-139.
41. Abstract 1542.
42. Abstract 2.
43. Bushell A, Karim M, Kingsley CI, Wood KJ. Pretransplant blood transfusion without additional immunotherapy generates CD25+CD4+ regulatory T cells: A potential explanation for the blood-transfusion effect. Transplantation 2003; 76: 449-455.
44. Jiang S, Camara N, Lombardi G, Lechler RI. Induction of allopeptide-specific human CD4+CD25+ regulatory T cells ex vivo. Blood 2003; 102: 2180-2186.
45. Abstract 380.
46. Abstract 1553.
47. Knechtle SJ, Burlingham WJ. Metastable tolerance in nonhuman primates and humans. Transplantation 2004; 77: 936-939.
48. Cai J, Lee J, Jankowska-Gan E et al. Minor H antigen HA-1-specific regulator and effector CD8+ T cells, and HA-1 microchimerism, in allograft tolerance. J Exp Med 2004; 199: 1017-1023.
49. - T cells and inhibit both T-cell proliferation and CTL function. Hum Immunol 2004; 65: 142-156.
50. Chang CC, Ciubotariu R, Manavalan JS et al. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 2002; 3: 237-243.
51. Abstract 382.
52. Narayanan K, Phelan D, Mohanakumar T. Effects of subsaturating anti-HLA antibodies on endothelial cells. Phosphatidylinositol 3-kinase/AKT mediated phosphorylation of bad in human aortic endothelial cells exposed to subsaturating concentrations of anti-HLA class I antibodies confers resistance against antibody-complement mediated cell death. Hum Immunol 2003; 64: S39.
53. Abstract 993.
54. Wijkstrom M, Kenyon NS, Kirchhof N et al. Islet allograft survival in nonhuman primates immunosuppressed with basiliximab, RAD, and FTY720. Transplantation 2004; 77: 827-835.
55. Abstract 4.
56. Abstract 1066.
57. Abstract 1067.
58. Abstract 1068.